In the 1960s, when the initial trials of combination chemotherapy began to prolong remission duration in childhood acute lymphoblastic leukaemia, an increasing incidence of central nervous system relapse was noted with rates between 50 and 70% (Hardisty & Norman, 1967; Evans et al., 1970; Hustu et al., 1973) . Overt CNS leukaemia appeared difficult to control, but its major significance was that it was almost invariably followed by bone marrow relapse, whilst deaths from neurological dysfunction were quite rare, even in the presence of multiple CNS recurrences (Ortega et al., 1987) . Symptom-free remission post overt CNS relapse was short and, in the MRC trials between 1977 and 1987, only 23 of 116 children survived without subsequent event. The length of first remission and whether relapse occurred on or off therapy significantly determined the chance of survival. There were serious long-term sequelae with 50% of survivors severely disabled neurologically, educationally or on both counts. A more favourable salvage rate of over 50% has been reported by the Paediatric Oncology Group but it is in a series with a shorter follow-up time (Land et al., 1985) . The full impact of disability caused by therapy requires long-term follow-up.
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Prevention of CNS relapse has clearly been deemed a better option than salvage post relapse. Although for some time controversial it is now accepted that CNS involvement results from leukaemic cells lying in the walls of superficial arachnoid veins which then migrate into the surrounding adventitia. As cell numbers increase the arachnoid trabeculae are destroyed with subsequent penetration of cerebrospinal fluid channels over the surface of the brain. (Aur et al., 1971; Hustu et al., 1973) . Whether such treatment prevents subsequent haematological relapse is more controversial. The Cancer and Leukaemia Group B in a randomised study showed a median remission duration of 26 months for those receiving intrathecal methotrexate compared with only 15 months for the group which did not (Holland & Glidwello, 1972) . In the St Jude's series of studies, there was a 2-3.5-fold increased risk of haematological relapse for those children who experienced an isolated CNS relapse. In the Total VI Study, 58% of patients who had received presymptomatic craniospinal irradiation remained in remission 8-11 years post-diagnosis, compared with only 35% of those given CNS treatment at the time of overt relapse (George et al., 1985) . In contrast, the CCGF101 study contained one arm in which patients were treated only with intrathecal methotrexate. This group had an increased CNS relapse rate, but neither marrow relapse nor overall survival rates were significantly affected after medium-term follow-up (Ortega et al., 1987) . However, these patients were Received 17 January 1990.
recalled for further therapy when the increased CNS relapses became obvious. With increasingly intensive induction and consolidation therapy longer term follow-up (beyond 10 years) is necessary in order to assess the full impact of any overt CNS disease upon total survival. For some patients it would appear that occult CNS leukaemia is the only site of residual disease which, if not eradicated, will cause problems by recurring and eventually reseeding the marrow. For others it is a marker of more widespread disease already present. In those, central nervous system control with irradiation alone would merely lead to the initial relapse occurring in a non-CNS site. (Nesbit et al., 1981) . For those with higher initial white cell counts there was a trend for better CNS control with 24 Gy (of borderline statistical significance).
It is the toxicity of this therapy which has caused particular anxiety and led to approaches which avoid combined modality therapy, particularly CNS irradiation, whenever possible. Acute neurotoxicity during cranial irradiation is rare apart from somnolence syndrome (symptoms maybe lessened by concomitant steroids), but immediate postradiotherapy severe immunosuppression, partial or complete growth hormone deficiency, premature onset of puberty and most significantly intellectual impairment are worrying sequelae from CNS therapy. Intellectual impairment is worst in children under 3 years at diagnosis and although they may function intellectually within the normal range they perform less well than siblings or peer group controls. Short-term memory appears to be specifically affected and this can be a major handicap in the achievement of basic numeracy and literacy (Eiser & Lansdown, 1977; Janoun, 1983) . To date the reduction from 24 to 18 Gy does not appear to decrease this risk. In the long term there may be a correlation between neuropsychological changes and abnormalities reported on CT and MRI scanning (Brouwers et al., 1985) . Although periventricular hypodensities may disappear with time it may be years before calcification develops, and therefore very long-term assessment is required before reliable conclusions can be drawn on toxicity.
The search is thus on for a group of children in whom cranial irradiation can be avoided without jeopardy to their survival and conversely identification of those where there is no alternative. Green et al. (1980) In the high risk patients the best relapse-free and total survival was obtained with irradiation. Where there was a high CNS relapse rate total survival was poorest, but where it was lowest it did not necessarily predict for overall good survival. The most important point appeared to be to achieve the best systemic leukaemia cell kill. This was a review and not a randomised concurrent trial and the systemic methotrexate dosages were low by current standards. High dose systemic therapy in dosages of 6-8 gm-2 give cytocidal concentrations (10-m) for 24-36 hours (Bleyer, 1989) . Appropriately phased folinic acid rescues normal cells outside the CNS and possibly blasts there, but not those within the CNS provided the rescue is given when the CSF methotrexate concentration falls below the concentration cytotoxic to the leukaemic cells. Such, therapy may not require the addition of intrathecal therapy. In a series of escalating dose studies the NCI and CCSG (Poplack et al., 1984) have showed that for intermediate and poor risk patients such methotrexate therapy is as effective as 24 Gy cranial radiotherapy with standard intrathecal methotrexate. They have also investigated the relative toxicities of the different forms of CNS treatment. Those irradiated showed a steady decline in verbal IQ and in full scale IQ whilst those receiving methotrexate demonstrated a slight increase in both parameters with a marginal fall in results of arithmetic tests. Patients who had been irradiated showed a decline in reading, spelling and arithmetic tests (Brouwers, 1987) . There must be some reservations about these observations. Follow-up is relatively short at 4-5 years and repeat testing can give spurious results. Most previous studies have suggested that postirradiation verbal IQ is relatively spared and that the normal deterioration is in non-verbal performance.
Some questions remain and we cannot be absolutely confident that there will be no long-term sequelae from these high doses of systemic methotrexate, (Eden et al., 1989) .
In the future, we may be able to define those girls who truly do not need any CNS treatment, meanwhile it would seem reasonable to try to avoid irradiation in those with standard risk (white count up to 50 x 109 I-') but use systemic methotrexate which may also afford some initial benefit in terms of overall disease-free survival. For the high risk patients matters are less clear, but a randomisation between irradiation and systemic methotrexate would appear justified. These form the basis of the next Medical Research Council ALL Trial with no change otherwise in the well established systemic treatment. The emphasis throughout must be upon total body leukaemia cell kill without overdue preoccupation with specific focal sites. High-dose systemic methotrexate in dosages between 6 and 10 g m2 seem to offer the chance of this without evidence to date of excessive toxicity. It is essential that such modern studies must incorporate assessment of toxicity.
